Carlos Fernández-Teruel (Carlos Fernandez-Teruel)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Topics

Particulate Matter

Squamous Cell Carcinoma

Oxidative Stress

Top Venues

Clinical pharmacokinetics

Cancer chemotherapy and pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Carlos Fernández-Teruel, Marie Cullberg, Cath Eberlein, Simon T Barry, Diansong Zhou
Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical pharmacokinetics 63 (8) (2024)
Carlos Fernández-Teruel, Marie Cullberg, Cath Eberlein, Simon T Barry, Diansong Zhou
Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical pharmacokinetics 63 (8) (2024)
Carlos Fernández-Teruel, Marie Cullberg, Cath Eberlein, Simon T Barry, Diansong Zhou
Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical pharmacokinetics 63 (8) (2024)
Carlos Fernández-Teruel, Marie Cullberg, Cath Eberlein, Simon T Barry, Diansong Zhou
Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical pharmacokinetics (2024)
Carlos Fernández-Teruel, Marie Cullberg, Cath Eberlein, Simon T Barry, Diansong Zhou
Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical pharmacokinetics 63 (8) (2024)
Carlos Fernández-Teruel, Salvador Fudio, Rubin Lubomirov
Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer. Cancer chemotherapy and pharmacology (2021)
Salvador Fudio, Josep Tabernero, Vivek Subbiah, Sant P Chawla, Victor Moreno, Federico Longo, Rafael Lopez, Antonio Anton, Jose Manuel Trigo, Geoffrey Shapiro, Woondong Jeong, Victor Manuel Villalobos, Rubin Lubomirov, Carlos Fernández-Teruel, Vicente Alfaro, Valentina Boni
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis. Cancer chemotherapy and pharmacology 87 (1) (2020)
Carlos Fernández-Teruel, Ignacio González-García, Iñaki F Trocóniz, Rubin Lubomirov, Arturo Soto, Salvador Fudio
Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer. Clinical pharmacokinetics 58 (3) (2020)